Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of ofatumomab in
combination with ICE chemotherapy in subjects with relapsed/refractory DLBCL following
failure to combination rituximab and anthracycline based chemotherapy. Participants with the
option of potentially curative stem cell therapy may proceed to high dose chemotherapy and
stem cell rescue. Participants with disease not considered curable with stem cell therapy,
ineligible for or decline stem cell therapy may receive up to a maximum of 6 cycles of study
drugs.